SDC

Characteristics of the Cohort Underpinning this Cross-Sectional StudyMethodsPart A: Metabolomics profiling and data preprocessingPart B: Drug deconfounding analysisPart C: Transcriptomics profiling and data preprocessingTable A1. Diagnosis and pharmacological treatment of 19 HIV-positive individuals with cardiovascular diseaseTable A2. Classification of metabolomic features as dysmetabolic, escalation, de-escalation and CVDTable A3. Classification of transcriptome features as dysmetabolic, escalation, de-escalation and CVDTable A4. Classification of metabolomic features as dysmetabolic, escalation, de-escalation and CVD as well as comparison based on the cardiometabolic disease spectrumTable A5. Pathway enrichment analysis of metabolome markers in the cardiometabolic disease spectrum in people living with HIVSupplementary Fig. S1 Operational classification of metabolome features from the perspective of CVD pathologySupplementary Fig. S2 Methodology employed for the classification of transcriptome features in the cross-sectional studySupplementary Fig. S3 Transcriptome features associated with CVD and its dysmetabolic pre-morbiditiesSupplementary Fig. S4 Functional enrichment analysis of transcriptome markers